Arcus Ventures

Arcus Ventures is a venture capital firm based in New York, specializing in investments in oncology-focused companies. Established in 2007, the firm targets early-stage companies that develop innovative biopharmaceuticals, new drug delivery platforms, and medical devices with pre-marketing approval. Additionally, it invests in service companies that demonstrate positive revenue, with a strong emphasis on proprietary technology and design. Arcus Ventures aims to support advancements in cancer treatment and related sectors, thereby contributing to the development of transformative healthcare solutions.

James B. Dougherty

Co-Founder and General Partner

Chad C. Hellmann

CFO

Steven L. Soignet

Founding / General Partner

24 past transactions

Cleave Therapeutics

Series C in 2019
Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Exosome Diagnostics

Series C in 2017
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Cleave Therapeutics

Series B in 2016
Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Exosome Diagnostics

Series B in 2016
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Exosome Diagnostics

Series B in 2015
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

XTuit Pharmaceuticals

Series A in 2015
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics that target the disease-promoting microenvironment associated with fibrotic diseases and cancer. Founded in 2011 and based in Waltham, Massachusetts, the company works on innovative pharmaceutical preparations aimed at diagnosing and treating oncological and inflammatory conditions. Its drug development pipeline includes micro-environment activated therapeutics that utilize pleiotropic mechanisms to inhibit the synthesis and stabilization of extracellular matrix and to silence activated stromal cells. Through these novel approaches, XTuit Pharmaceuticals seeks to improve cancer therapies by addressing the tumor microenvironment effectively.

TRACON Pharmaceuticals

Series B in 2014
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing and commercializing targeted therapeutics for cancer and wet age-related macular degeneration (AMD). The company's lead product is envafolimab, an investigational PD-L1 single-domain antibody aimed at treating soft tissue sarcoma. Other notable candidates include DE-122, which is undergoing a randomized Phase IIa study for wet AMD; TRC102, a small molecule currently in multiple clinical trials for various cancers, including mesothelioma and lung cancer; TRC253, in Phase II trials for metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody in Phase I development for solid tumors. TRACON has established collaborations and licensing agreements with several organizations, including 3D Medicines and Janssen Pharmaceutica, to advance its product development. TRACON was originally founded in 2004 and underwent a name change from Lexington Pharmaceuticals in 2005.

Epic Sciences

Series C in 2014
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Exosome Diagnostics

Series B in 2014
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

MI Bioresearch

Series B in 2013
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

T2 Biosystems

Series E in 2013
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.

MI Bioresearch

Series A in 2012
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

Oncoscope

Seed Round in 2011
Oncoscope, Inc. is a medical device company based in Durham, North Carolina, established in 2006. The company specializes in developing optical imaging systems that focus on epithelial tissues located in various parts of the body, including the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder. Its innovative systems deliver in vivo measurements that provide critical information on tissue microstructure, specifically assessing the diameter and density of cell nuclei. This technology aims to improve clinical outcomes by offering detailed insights into the health of epithelial tissues.

T2 Biosystems

Series D in 2011
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.

MI Bioresearch

Series A in 2011
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

TRACON Pharmaceuticals

Series A in 2011
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing and commercializing targeted therapeutics for cancer and wet age-related macular degeneration (AMD). The company's lead product is envafolimab, an investigational PD-L1 single-domain antibody aimed at treating soft tissue sarcoma. Other notable candidates include DE-122, which is undergoing a randomized Phase IIa study for wet AMD; TRC102, a small molecule currently in multiple clinical trials for various cancers, including mesothelioma and lung cancer; TRC253, in Phase II trials for metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody in Phase I development for solid tumors. TRACON has established collaborations and licensing agreements with several organizations, including 3D Medicines and Janssen Pharmaceutica, to advance its product development. TRACON was originally founded in 2004 and underwent a name change from Lexington Pharmaceuticals in 2005.

Vascular Pathways

Series B in 2010
Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.

Clear Vascular

Venture Round in 2010
Clear Vascular, Inc. is a clinical-stage company focused on developing innovative pharmaceutical products for the treatment of cardiovascular diseases. Founded in 2005 by Dr. Gilbert Gonzales, the company specializes in imaging and therapeutically addressing vulnerable plaque and other vascular inflammatory conditions. Their primary product, Tin-Annexin, utilizes tin-117m, a radioisotope developed in collaboration with the US Department of Energy and Brookhaven National Laboratory. This product has undergone various pre-clinical and clinical trials, demonstrating its effectiveness in both imaging and treating inflammatory tissues associated with unstable plaque. The production of tin-117m has evolved through advanced methods, including a proton accelerator and an innovative technique developed by Dr. Nigel Stevenson, which employs alpha particles and cadmium-116 as a target material. This allows for scalable manufacturing of the product, enhancing the potential for timely treatment for patients suffering from cardiovascular issues.

T2 Biosystems

Series C in 2010
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.

Oncoscope

Venture Round in 2010
Oncoscope, Inc. is a medical device company based in Durham, North Carolina, established in 2006. The company specializes in developing optical imaging systems that focus on epithelial tissues located in various parts of the body, including the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder. Its innovative systems deliver in vivo measurements that provide critical information on tissue microstructure, specifically assessing the diameter and density of cell nuclei. This technology aims to improve clinical outcomes by offering detailed insights into the health of epithelial tissues.

Palyon Medical

Series A in 2009
Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

MacroGenics

Series D in 2008
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's pipeline includes several immuno-oncology candidates, such as Margetuximab, a monoclonal antibody currently in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include various monoclonal antibodies targeting immune checkpoints like PD-1 and B7-H3, as well as combination therapies that leverage multiple targets. MacroGenics employs advanced Fc engineering technology to enhance antibody functionality and is also exploring applications for autoimmune disorders and infectious diseases. The company has established strategic collaborations with several partners to advance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics to address significant medical needs.

Palyon Medical

Seed Round in 2008
Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

Genta

Venture Round in 1991
Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of people with cancer. Genta has built a broad portfolio of proprietary products in various stages of clinical development. The Company’s drugs include Ganite (gallium nitrate injection), tesetaxel, and oral gallium.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.